Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
VRTXthis companyVertex Pharmaceuticals Incorporated	$543.06	29.32×	6.21×	9.6×	23.57×	-37.8%	85.0%	39.4%	32.7%	21.2%	18.1%	2.8%	0.21×	-0.25×	357.95×	2.9×	0.0%	5	9.14	4	A-
ALNYAlnylam Pharmaceuticals, Inc.	$155.89	166.38×	66.01×	14.03×	81.9×	-1017.9%	81.8%	13.5%	8.4%	39.8%	13.7%	0.9%	1.62×	-0.6×	1.99×	2.76×	0.0%	5	3.79	4	A-
BBIOBridgeBio Pharma, Inc.	$74.41	-20.18×	-7.27×	30.05×	-25.49×	-271.4%	94.4%	-113.3%	-145.3%	35.1%	-108.5%	-3.0%	-1.31×	-3.19×	-10.72×	2.62×	0.0%	2	-0.07	2	C
BEAMBeam Therapeutics Inc.	$27.00	-34.22×	2.21×	19.62×	-196.25×	-229.8%	84.0%	-274.6%	-57.2%	-6.5%	-27.4%	-13.1%	0.24×	0.08×	-8.77×	13.09×	0.0%	2	4.01	1	C-
BMRNBioMarin Pharmaceutical Inc.	$55.98	32.65×	1.87×	3.54×	18.73×	-87.5%	77.1%	16.6%	10.8%	5.7%	5.6%	6.4%	0.11×	-1.17×	48.95×	5.21×	0.0%	3	0.33	3	B
IONSIonis Pharmaceuticals, Inc.	$28.19	-33.24×	25.88×	13.41×	-52.41×	-292.2%	98.3%	-40.5%	-40.4%	-77.9%	-12.0%	-2.5%	5.35×	-7.89×	-4.22×	3.83×	0.0%	2	0.89	1	D+
Peer median	—	-20.18×	2.21×	14.03×	-25.49×	-271.4%	84.0%	-40.5%	-40.4%	5.7%	-12.0%	-2.5%	0.24×	-1.17×	-4.22×	3.83×	0.0%	2	0.89	2	—